Asha Pharma

Asha Pharma is a private, US-based CRO founded in 2018, focused on the critical early-stage development work of solid form discovery and optimization. The company leverages over 25 years of team experience and state-of-the-art analytical instrumentation to help pharmaceutical clients identify optimal solid forms (polymorphs, salts, cocrystals) to improve drug solubility, stability, and manufacturability. Operating as a service provider, Asha Pharma generates revenue by offering these specialized technical services, which are designed to reduce overall drug development costs and timelines for its clients. Its business model is built on deep expertise in crystallization science and preformulation, serving the broader small molecule drug development sector.

Integrated service workflow for solid form screening and characterization, utilizing state-of-the-art analytical instrumentation (PXRD, DSC, TGA, DVS) and expertise in polymorphism, salt/cocrystal formation, and crystallization process development.

Asha Pharma competes in the specialized solid-state CRO segment against other boutique labs and the early-development service divisions of large, global CROs (e.g., Charles River, Labcorp, Eurofins). Its differentiation is based on deep, focused expertise in crystallization, a high-touch service model, and specific capabilities like DEA-controlled substance handling. Competition also comes from in-house teams at large pharmaceutical companies.